Tiziana Life Sciences (TLSA) Insider Cerrone Buys $17K of Stock

Gabriele Cerrone, an insider, recently increased his stake in TLSA by purchasing 15,000 shares. The transaction occurred on June 12, 2026, at an average price of $1.11 per share, totaling a value of $16,650. This move was not part of a pre-arranged trading plan.

Other Institutional Activity in TLSA

Several institutional investors have also been active in TLSA. Dauntless Investment Group, LLC increased its holdings by 405,449 shares, bringing its total to 2,165,231 shares valued at approximately $2,533,320. Meanwhile, Marshall Wace, LLP reduced its position by 124,451 shares, ending with 157,566 shares worth about $184,353. Zhang Financial LLC added 12,000 shares to hold 111,900 shares valued at $130,923. UBS Group AG and Focus Partners Wealth slightly trimmed their positions, while Geode Capital Management, LLC maintained its holdings without change.

Tiziana Life Sciences Ltd Stock Up 21.5%

TLSA shares are currently trading around $1.10. The stock has seen varied institutional interest, with significant buying and selling activity. Analyst coverage includes a reiterated buy rating from B.Riley Financial, reflecting some optimism about its future performance.

Analysts Set New Price Targets

On May 5, 2023, B.Riley Financial reiterated its buy rating for TLSA, setting a price target of $3.00. This indicates confidence in the company's potential upside, despite the current low trading price.

Bottom Line

Gabriele Cerrone's recent purchase of TLSA shares highlights ongoing insider interest in the stock. Institutional investors have shown mixed activity, with some increasing and others decreasing their positions. While past insider buying can be a positive signal, it's essential to consider the broader market context and analyst perspectives, such as B.Riley Financial's optimistic price target.